A Retrospective Study of Assessing the Risk Factors for Brain Metastasis in Patients with Breast Cancer
DOI:
https://doi.org/10.65129/medical.v1i2.34Keywords:
Brain Metastasis, Breast Cancer, Metastatic Breast CancerAbstract
Breast cancer is the most common malignancy among women worldwide and remains a leading cause of cancer-related mortality. Brain metastases represent a devastating complication associated with neurological decline and poor prognosis. Breast cancer is the second most common cause of brain metastases after lung cancer, and incidence has been rising partly due to improved systemic therapies that prolong survival but inadequately penetrate the blood-brain barrier. Approximately 10-30% of patients with advanced breast cancer develop brain metastasis during their disease course. This retrospective study aims to identify clinical and pathological predictors of brain metastasis in breast cancer and to develop a risk prediction model, thereby facilitating early detection and guiding individualised management strategies.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Medical and Medical Specialities
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004; 22(17):3608-3617. https://doi.org/10.1200/JCO.2004.01.175.
2. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006; 17(6):935-944. https://doi.org/10.1093/annonc/mdl064 PMid:16603601.
3. Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016; 127(3):407-414. https://doi.org/10.1007/ s11060-016-2075-3 PMid:26909695.
4. Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H. Breast cancer brain metastases: Biology and new clinical perspectives. Breast Cancer Res BCR. 2016; 18:8. https://doi.org/10.1186/s13058-015-0665-1 PMid:26781299 PMCid: PMC4717619.
5. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005; 167(4):913-920. https://doi.org/10.1016/S00029440(10)61180-7 PMid:16192626.
6. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006; 17(6):935-944. https://doi.org/10.1093/annonc/ mdl064 PMid:16603601.
7. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007; 110(12):2640-2647. https://doi.org/10.1002/cncr.23088 PMid: 17960791.
8. Smedby KE, Brandt L, Bäcklund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Brit J Can. 2009; 101:1919-1924.
9. Azim HA, Abdel-Malek R, Kassem L. Predicting brain metastasis in breast cancer patients: Stage versus biology. Clin Breast Cancer. 2018; 18(2):e187-e195. https://doi.org/10.1016/j.clbc.2017.08.004 PMid:28888580.
10. Koniali L, Hadjisavvas A, Constantinidou A, Christodoulou K, Christou Y, Demetriou C, et al. Risk factors for breast cancer brain metastases: A systematic review. Oncotarget. 2020; 11(6):650-669. https://doi.org/10.18632/oncotarget.27453 PMid:32110283 PMCid:PMC7021234.
11. Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, et al. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab. Breast Edinb Scotl. 2016; 25:22-26. https://doi.org/10.1016/j.breast.2015.11.006 PMid:26801412.
12. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behaviour of breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2010; 28(20):3271-3277. https://doi.org/10.1200/JCO.2009.25.9820 PMid:20498394.
13. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T- DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. Ann Oncol Off J Eur Soc Med Oncol. 2015; 26(1):113-119. https://doi.org/10.1093/annonc/ mdu486 PMid:25355722 PMCid:PMC4679405.
14. Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: Differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole- brain radiotherapy (WBRT). Ann Oncol Off J Eur Soc Med Oncol. 2010; 21(5):942-948. https://doi.org/10.1093/annonc/mdp407 PMid:19840953.
15. Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol Off J Am Soc Clin Oncol. 2020; 38(32):3773-3784. https://doi.org/10.1200/JCO.20.01255 PMid:32931399 PMCid:PMC7655019.
16. Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One. 2014; 9(2):e89389. https://doi.org/10.1371/journal.pone.0089389 PMid:24586742 PMCid:PMC3933537.
